AstraZeneca introduces intravenous formulation of Nexium in Sweden
LONDON, ENGLAND, August 27, 2003 -- AstraZeneca announced, after receiving its first approval from the Swedish Medical Products Agency (MPA), that it will launch the new intravenous (i.v.) formulation of the proton pump inhibitor (PPI) Nexium, providing an opportunity for physicians to treat patients suffering from gastroesophageal reflux disease (GERD) who are unable to take oral therapy.
Nexium administered intravenously demonstrates the same efficacy as oral Nexium -- the first PPI to have shown superior control of gastric acid secretion compared with all other oral PPIs.
"Some patients, like those in intensive care units, are unable to take oral therapy due to their critical condition. The introduction of the Nexium i.v. formulation provides these patients with a suitable alternative with the same, high efficacy as the oral formulation," said Dr Ola Rönn, Vice President and Head of the Gastrointestinal Therapy Area, AstraZeneca. "We are currently seeking approval for this new formulation in a number of other markets, as well as additional indications for Nexium, both of which will ensure that new patient groups can get the beneficial treatment effects of Nexium."
Nexium administered intravenously has been shown to provide acid control for as many hours with intragastric pH>4 as oral Nexium in a double-blind, randomised, two-way crossover study. Nexium i.v. is available in a single vial containing 40 mg for both infusion and injection. This convenient presentation means nurses and physicians can administer 20 or 40 mg from one single vial for either infusion or injection and it is also convenient for hospitals and pharmacists to stock.
Posted: August 2003